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ABSTRACT 
 
Calcitriol, the active metabolite of Vitamin D3, is a potential anticancer agent but 
exhibits several drawbacks as low bioavailability and high toxicity. Therefore, new therapeutic 
strategies, as specific drug delivery systems, must be developed in order to overcome those 
limitations. In this work, Vitamin D3 metabolites were encapsulated in poly(lactide-co-
glycolide) nanoparticles (PLGA NPs). PLGA nanoparticles with controlled sizes and properties, 
as nanocarriers of cholecalciferol and calcitriol, were prepared using the single emulsion-
solvent evaporation technique. Two formulation parameters, vitamin/polymer ratio and 
sonication time, were studied and discussed using cholecalciferol as a drug model. After 
synthesis, the PLGA NPs with and without Vitamin D were analyzed in terms of size, shape and 
zeta potential. The attained systems for calcitriol showed mean diameters smaller than 200 
nm, encapsulation efficiency of 57%, a loading capacity of approximately 6% and a process 
yield of 57%. The PLGA NPs remained stable at storage conditions for several weeks and they 
were lyophilized to increase their shelf-life. Studies on calcitriol release from the PLGA NPs 
have shown a biphasic pattern with an initial burst release, attributed to the surface-adsorbed 
vitamin, followed by a slower controlled release, correspondent to the calcitriol entrapped 
inside the NPs’ matrix. The cytotoxic effect of calcitriol encapsulated in PLGA NPs was 
evaluated on two human pancreatic cells lines, hTERT-HPNE and S2-013. The in vitro studies 
demonstrated that bare PLGA NPs are biocompatible and the antineoplastic effect of calcitriol 
against human pancreatic cancer cells is enhanced by the nanoparticle formulation in terms of 
cell survival and growth. From the attained results, it was possible to conclude that PLGA NP 
formulation is a suitable nanocarrier for vitamin D3 active metabolites, since they are able to 
improve therapeutic efficiency and potentially reduce calcitriol toxic effects in normal tissues. 
 
Keywords: PLGA Nanoparticles, Poly(lactide-co-glycolide), Vitamin D3, Calcitriol, 1,25 
Dihydroxyvitamin D3, Cancer Therapy, Drug Delivery, Nanocarrier 
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1 INTRODUCTION 
 
1.1 Motivation 
 
Cancer is the main cause of death worldwide. Despite the advances in medicine and 
technology fields, the aging and increase of the world’s population has led to a raise in cancer 
incidence [1]. Although chemotherapeutic agents are effective in cancer treatment, their  
success  is largely  hindered  as  a  result  of acting indiscriminately on both tumor and healthy 
tissues, inadequate accessibility  of antineoplastic agents to tumor  tissue,  requiring  high  
doses,  rapid abolition,  poor  solubility  and  inconsistent  bioavailability [2].  In more recent 
years, Vitamin D3 exhibited a major role in tumor’s pathogenesis, progression and therapy [3]. 
Although as other chemotherapeutic agents, the use of Vitamin D3 also exhibits several 
drawbacks. These limitations are recently leading to numerous investigations in order to 
design and develop an ideal formulation for Vitamin D3 delivery to cancer cells.  
A growing effort has being applied to find novel approaches for cancer treatment and 
in recent years a growing number of studies, focused on the research and development of 
nanoparticles as drug delivery systems, have been conducted. For that purpose, the 
nanosystem must meet several requirements such as biocompatibility, biodegradability, 
mechanical strength, FDA- approved and process synthesis low complexity. Nowadays, one of 
the most attractive candidates is Poly(lactide-co-glycolide)(PLGA), which is a co-polymer of 
poly lactic acid (PLA) and poly glycolic acid (PGA) [4-6]. As the success of a cancer therapy 
depends not only on the pharmacokinetic and pharmacodynamic activity of the therapeutic 
agent, but to a large extent, on its bioavailability and toxicity [4], the development of a 
nanocarrier for Vitamin D will allow to enhance its anti-cancer activity. 
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1.2 Main objectives 
 
The main aim of the present work is to develop a suitable PLGA-based nanocarrier for 
vitamin D active metabolites, and evaluate the capacity of this polymeric system to improve 
therapeutic efficiency and reducing toxic effects. For that purpose, PLGA nanoparticles with 
controlled sizes and properties were prepared in this study, as nanocarriers of cholecalciferol 
and calcitriol. Their synthesis was complemented with physicochemical characterization of 
structure and properties as well as the evaluation of their effect on two human pancreatic cells 
lines, hTERT-HPNE and S2-013. Although some studies, among Vitamin D3 encapsulation, have 
been conducted, the use of PLGA nanoparticles for Vitamin D3 delivery towards cancer 
treatment was never reported. 
 
1.3 Thesis organization 
 
This dissertation is organized into five chapters. This chapter, “Introduction”, presents 
the subject and main objectives of this research work. Chapter 2, “State of the art”, presents 
an overview of the Vitamin D3 metabolites and PLGA nanoparticles, as also a review on the 
studies that have been developed so far on the Vitamin D3 delivery. Chapter 3, “Materials and 
methods” focus on the main materials and methodologies used in this experimental work. On 
chapter 4, “Results and Discussions”, the attained results and respective discussion for the 
Vitamin D3-loaded PLGA nanoparticles characterization and evaluation are presented. Finally, 
an overall summary about this study, its main conclusions and some future work perspectives 
are presented on Chapter 5, “Concluding remarks and future perspectives”. 
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2 STATE OF THE ART 
 
2.1 Classic cancer therapy challenges 
 
Cancer is considered the 21st Century’s disease being one of the main causes of death 
worldwide. Despite the advances in medicine and technology fields, the aging and increase of 
the world’s population has led to a raise in cancer incidence. In fact, the last statistic study 
carried out by GLOBOCAN project, in 2008, state that about 12.7 million cancer cases and 7.6 
million cancer deaths are estimated to occur per year [1]. This sort of studies allows adopting 
the most suited strategies to improve cancer treatment and to focus on prevention, early 
diagnosis and more effective therapies. Surgery, radiotherapy and chemotherapy are the most 
used cancer therapies. Surgery and radiotherapy are examples of local therapies. Moreover, 
chemotherapy is considered as a systemic therapy, which enters the bloodstream and destroy 
or control cancer cells. Chemotherapy is probably the most common treatment, however 
chemotherapeutic agents are not able to differentiate between healthy and tumor tissue and 
so will act on tissues without discrimination, resulting in devastating side-effects. Among these 
are increased susceptibility to infections, fertility problems and healthy tissues destruction. 
Concluding, although chemotherapeutic  agents are effective in cancer treatment,  their  
success  is largely  hindered  as  a  result  of  the  inadequate  accessibility  of antineoplastic  
agents  to  tumor  tissue,  lack of specificity, requiring  high  doses,  rapid abolition,  poor  
solubility, devastating side effects and  inconsistent  bioavailability  [2, 7]. Therefore, the 
continuous research for an ideal therapy is very important. In fact, nanomedicine can bring an 
important contribution in this search. 
 
2.2 Nanoparticles as Drug Delivery Systems for cancer therapy 
 
Nanotechnology  has proven to be extremely advantageous in creating breakthroughs 
in diagnosis, treatment and monitoring of cancer, enabling early diagnosis and the controlled 
delivery of drugs [8].  In fact, a growing number of studies focused on the research and 
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development of nanoparticles as drug delivery systems (DDS) has been published. 
Nanoparticles are colloidal carriers with dimensions on the nano scale (10-9m) with unique 
physicochemical properties as small size, larger surface area, stability, varied composition, 
biocompatibility and biodegradability [7, 9].  
Encapsulating drugs in a nanocarrier has the following main objectives: to increase 
drug’s bioavailability and bioaccumulation in the target site, and decrease drug’s toxicity. The 
fulfillment of these main goals allows maximizing therapeutic effects and minimizing side 
effects. These goals are achieved by drug encapsulation itself, but also by modifying NPs’ 
surface. The encapsulation of the drug minimizes premature degradation after administration, 
since it allows protection and stabilization of the drug against environmental factors. This drug 
increased stability ensures enhanced bioavailability. Also in order to increase the bioavailability 
of the drug, the functionalized NP allows overcoming the biological barriers that would lead to 
its elimination. The toxicity of the drug is also reduced since NPs allows the use of lower doses, 
since the delivery is localized rather than systemic. Also a decrease in toxicity is due to drug 
being less likely to act on healthy cells, since it is possible to direct NP to the diseased tissues, 
increasing accumulation in the target tissues.  
NPs benefit from tumor’s environment through passive targeting. The size of the drug-
loaded NP alone is bigger than the free form of the drug. This brings an advantage in using NPs 
to cancer therapy due to increased Enhanced Permeability and Retention effect (EPR effect) of 
such tissues. As it is illustrated in figure 1, tumor tissues exhibit an increased permeability of 
blood vessels, while lymphatic drainage is decreased. This leads to an increase in the 
concentration of drug-loaded nanoparticles in the tumor tissue [10, 11]. However the vessels 
permeability is not homogeneous and a more selective approach needs to be used for NPs 
drug delivery treatment. As this EPR effect is not verified in healthy tissues, NPs permeability is 
hampered. Also DDS that depends only on passive targeting mechanisms are specificity-
limited. Therefore active targeting strategies should be developed [7].  
 
Figure 1 |  Representation of the EPR effect in tumor tissue [4]. 
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Ideally, for therapeutic use NPs should remain in circulation during the appropriate 
time, to be present at the target site in adequate amounts and improve the therapeutic 
efficacy. To be as efficient as possible, NP should meet certain requirements as being non-
invasive, easy to prepare, economically viable and clearly a small and controlled size. If their 
surface is charged, the stability will be enhanced, due to the repulsion between them that 
hinders aggregation. NPs also must have a high loading capacity to allow carrying a large 
amount of drug [2, 12-14]. The efficiency of a therapeutic system for cancer’s treatment is 
evaluated by its ability to reduce and destroy tumor cells minimizing the damage of the 
healthy tissues. This is where is highlighted the major contribution of NPs as nanocarriers of 
anticancer drugs, as they enable a targeted distribution into specific tissues [15]. Also NPs 
allow maintaining active doses of the drug for long periods of time, due to their controlled and 
sustained release. Another main goal of the use of NPs is that it is possible to address a specific 
therapy for each patient using tumor cell markers specific to each individual. The 
functionalization of the NP with these markers will result in a much more efficient therapy 
[10].  
Currently, the most studied NPs for cancer nanotherapy are liposomes, polymeric and 
lipidic NPs, dendrimers, micelles, carbon and silica nanotubes (figure 2).  However, although 
the extensive research, liposomes, lipidic and polymeric NPs are, at the moment, the only FDA-
approved and clinically available formulations for cancer treatment [11]. Table 1 summarizes 
the commercially available nanoparticle-based therapeutic products for cancer therapies. 
 
 
Figure 2 | Representation of different types of nanocarriers for drug delivery [11]. 
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Table 1 | Clinically approved nanoparticle-based cancer therapeutics. 
Table prepared based on the following references: [15-22]. 
(1)
 Pegylated liposomal doxorubicin is known as Doxil® only in USA, and it is known as Caelyx® elsewhere.  
Nanocarrier Drug
(1) Doxil ® Ortho Biotech Pegylated-Liposome Doxorubicin
Refractory Kaposi’s sarcoma, metastic 
breast and ovarian cancer
Intramuscular 
injection
Nov, 1995 [15-19,21]
(1) Caelyx® Schering Plough Pegylated-Liposome Doxorubicin
Refractory Kaposi’s sarcoma, metastic 
breast and ovarian cancer
Intramuscular 
injection
Nov, 1995 [15-19,21]
DaunoXome®
Diatos/Gilead 
Sciences
Liposome Daunorubicin HIV-related Kaposi’s sarcoma
Intravenous 
injection
April, 1996 [15-19,21]
DepoCyt® SkyePharma Liposome Cytarabine Lymphomatous meningitis
Intrathecal 
injection
April, 1999 [16,18,21]
Lipusu® Luye Pharma Group Liposome Paclitaxel
Metastatic ovarian and breast cancer; 
Lung cancer patients who cannot be 
treated with operation or radiotherapy
Intravenous 
injection
Only approved in 
China
[20]
Myocet TM
Zeneus Pharma/Elan 
Pharmaceuticals
Liposome Doxorubicin
Metastic breast and ovarian cancer, 
and Kaposi’s sarcoma
Intravenous 
injection
Only approved in 
Europe and Canada
[15-16,18-
19,21]
Abraxane® Abraxis Bioscience Albumin-bound nanoparticles Paclitaxel
Metastatic breast cancer; Lung cancer 
patients who cannot be treated with 
operation or radiotherapy
Intravenous 
injection
Jan, 2005
[15-16,18-
19,21]
Genexol ® -PM Samyang Pegylated-PLA Paclitaxel
Metastatic breast cancer; Lung and 
pancreatic cancer
Intravenous 
injection
Only approved in 
South Korea; 
Currently is on 
phase II in the USA
[16,21]
Nanoxel® Dabur Pharma Pegylated-PLA Paclitaxel
Metastic breast and ovarian cancer, 
and Kaposi’s sarcoma
Intravenous 
injection
Only approved in 
India
[22]
Oncaspar ® Enzon Polyethylene glycol L-asparaginase Acute lymphoblastic leukemia
Intravenous or 
intramuscular 
injection
Feb, 1994 [16,19,21]
References
Composition
Trade name
Pharmaceutical 
Company
Indication
Administration 
route
FDA approval date
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2.2.1 PLGA Nanoparticles  
 
Suitable nanomaterials for drug delivery must meet several requirements such as 
biocompatibility, biodegradability, mechanical strength, FDA- approved and process synthesis 
low complexity. One of the most attractive candidates is Poly (lactide-co glycolide)acid (PLGA), 
which is a co-polymer of poly lactic acid (PLA) and poly glycolic acid (PGA) linked by ester 
bonds as it is shown is figure 3 [4-6]. Although constituted by natural monomers, this is a 
synthetic polymer. Its adjustable biodegradation rate, strength and tunable mechanical 
properties justify its growing popularity. Also, its special features allow protection of drug from 
degradation and sustained release delivery [5]. 
 
Figure 3 | Chemical structure of poly lactic-co-glycolic acid. m represents the number of lactic acid units and n is the 
number of glycolic acid units.  
Biodegradability is a main feature of PLGA, since it can be used without the need for a 
surgical procedure to remove it [5]. It is well established that PLGA biodegradation occurs by 
hydrolytic cleavage of its esters linkages into monomers, glycolic and lactic acid [4-6, 23-27]. 
The degradation mechanism and reaction products of PLGA hydrolysis are represented in 
figure 4.  
 
Figure 4 | Representation of hydrolytic degradation of PLGA and its products [6]. 
 
During hydrolysis the increasing number of free carboxylic end-groups lead to matrix 
swelling and increasing of hydrophilicity which enhances water-uptake [25]. These acidic 
products accumulate inside the PLGA NPs and are responsible for reaction auto-catalysis [25, 
26]. The hydrolytic breakdown also causes the formation of pores in the matrix of the 
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polymeric system [23]. Many factors have been associated with the PLGA tunable degradation 
rate, such as: drug loading and type, polymer average molecular weight, polymeric molecular 
weight distribution, ratio of lactide to glycolide, effect of pH, porosity, cristalinity of the co-
polymer [5, 23, 25-27].  
Since PLGA decomposition products can be eliminated from the body by metabolic 
pathways, such as via the citric acid cycle (Krebs cycle), or directly by renal excretion, there is a 
minimal systemic toxicity associated [6]. Figure 5 schematizes how these metabolites are 
eliminated. 
 
Figure 5 | Schematic representation of biological elimination pathways of PLGA biodegradation process. Lactic and 
glycolic acid enter the Krebs cycle and subsequently are eliminated from the body as carbon dioxide and water. In 
addition to this pathway, glycolic can also be excreted unchanged in the kidney. Adapted from: [6]. 
Although not causing tissue damages, PLGA NPs are not able to remain for a long time 
in blood stream because they are usually recognized by the immune system. Though, the size 
of the PLGA NP is extremely important with respect to blood circulation time [4]. If the system 
is smaller than 100 nm, the plasma protein adsorption to the NP surface is almost negligible, 
and the immune system is unable to eliminate NPs [27]. For NPs over 100 nm, their surface 
must be functionalized with biomolecules to increase blood circulation half-life. One of the 
most used strategies is coating their surface with a biodegradable copolymer with hydrophilic 
characteristics such as polyethylene glycol (PEG) [24]. However, passive targeting by choosing 
the size is not always sufficient in order to direct NPs to target tissues. To target cancer cells, 
several functionalized PLGA systems can be produced to enhance drug accumulation in the 
target area, recognition and binding to the target cell or tissue. For example, it is possible to 
modify their surface with folate, RGD, transferrine or specific antibodies [24, 28, 29]. 
Once they are recognized, PLGA NPs enter the target cell through receptor-mediated 
endocytosis. The acidic medium of late endosome triggers a charge change in PLGA NP. The NP 
becomes cationic leading to destabilization of late-endossomal membrane allowing efflux of 
NP and drug release, as it is shown in figure 6. Endosome-lysosome pathway is characterized 
by two types of compartments, the endosome and lysosome. Lysosomes are usually regarded 
as the terminal degradation compartment of this pathway. One important feature of PLGA NPs 
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is that they are cationic only in the endosomal compartment and do not destabilize the 
lysosomes, unlike another kinds of NPs. This allows to reduce their toxicity [4]. Another major 
advantage in the use of PLGA NPs is their ability to avoid the recognition of the P-glycoprotein, 
which is one of the main cells’ drug resistance mechanisms [30]. 
 
 
Figure 6 | Image illustrating PLGA NP endolysosomal efflux and drug release [4]. 
 
As the amount of encapsulated drug depends upon the drug’s chemical structure and 
its interactions with PLGA [6], also several factors affect the PLGA NPs’ release profile such as: 
(1) physico-chemical properties of the encapsulated drug; (2) geometry of drug-loaded PLGA 
NPs (size and shape); (3) drug solubility; (4) loading efficiency [6, 23, 26]. The main pathways 
for drug release in PLGA NPs are: (1) desorption of drug bound to the surface, (2) diffusion 
through NP matrix, (3) NP matrix hydrolysis,(4) or a combined degradation-diffusion process 
[5, 6, 23, 26]. PLGA NPs generally exhibit a biphasic release profile, characterized by an initial 
burst due to the release of surface-adsorbed drugs; followed by a biodegradation-accelerated 
release until complete polymer solubilization [6, 25]. This final phase is a combination of 
biodegradation-diffusion process [25]. Since adverse side effects of anti-cancer drugs are 
associated with high doses, this release pattern of PLGA NPs will allow a reduction of toxicity. 
This controlled and sustained release prevents high doses accumulation. Also, these slow 
release allow diminishing administration frequency, since drug levels are maintained over long 
periods of time [6]. 
PLGA NPs can be produced using several techniques. The characteristics of the 
obtained NP, as size and structural organization, depend upon the chosen method and 
solvents [5, 31, 32]. The most common methods are single or double-emulsion solvent 
evaporation and nanoprecipitation [6]. While nanoprecipitation is suitable for the entrapment 
of both hydrophobic and hydrophilic drugs [33], the choice of single or double emulsion 
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depends upon the hydrophilicity of the drug to be encapsulated [5]. Single-emulsion is a 
suitable choice for encapsulating hydrophobic drugs, and double-emulsion is mostly used for 
hydrophilic drugs [5, 32]. In nanoprecipitation method a precipitation of a dissolved material 
as nanoscale particle occurs after exposure to a non-solvent that is miscible with the solvent 
[34]. In contrast, in solvent evaporation technique, particles are formed from submicron 
emulsion droplets when immiscible solvents are mixed [33]. 
The extensive research around PLGA and the many systems already available in the 
market testify for the great success of this biomaterial. Tables 2 and 3 presented below 
summarize some of the PLGA applications clinically available, as also some applications in 
development or clinical trial phases. 
Table 2 | Commercially available PLGA based particles formulations. 
 
Trade name 
Pharmaceutical 
Company 
Drug Indication 
Administration 
route 
FDA 
approval 
date 
References 
Lupron Depot® 
TAP 
Pharmaceuticals 
Leuprolide 
acetate 
Hormone-
dependent cancers 
Intramuscular 
injection 
Jan, 1989 [25, 35] 
Sandostatin 
LAR® Depot 
 
Novartis 
Octreotide 
acetate 
Acromegaly 
Intramuscular 
injection 
Nov, 1998 [25, 35] 
Somatuline® LA Ipsen 
Lanreotide 
acetate 
Acromegaly 
Subcutaneous 
injection 
Aug, 2007 [25, 35] 
Telstar® 
Pfizer / Watson 
Pharmaceuticals 
Triptorelin 
pamoate 
Prostate Cancer 
Intramuscular 
injection 
June, 2001 [25, 35] 
Vivitrol® 
Alkermes Inc. / 
Cephalon Inc. 
Naltrexone 
Management of 
alcohol and opioid 
dependence 
Intramuscular 
injection 
April, 2006 [25, 35] 
Nutropin 
Depot® 
Genentech Somatropin 
Growth hormone 
deficiency 
Subcutaneous 
injection 
Dec, 1999 [25, 35] 
Table prepared based on the following references: [25, 35]. 
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Table 3 | Currently developed PLGA-based particles as drug delivery systems for the treatment 
of different pathologies.  
Table prepared based on the following references: [18, 36-46] . Note that PMSA stands for Prostate-specific 
membrane antigen, EGFR for epidermal growth factor receptor and PEG for polyethylene glycol. 
Despite the fact that PLGA NPs are widely used in medical applications, their use faces 
a few limitations as their poor loading capacity. The burst release mentioned above can be 
another major pitfall since large amounts of drug is loss before reaching the target tissue, 
resulting in an efficacy loss of the DDS.  Also, the many required steps for NP production such 
as centrifugation and dialysis are expensive and difficult to scale-up [32]. PLGA NPs also exhibit 
a size-dependent cytotoxicity. Small PLGA NPs may trigger the generation of reactive oxygen 
species, mitochondrial depolarization and inflammatory cytokines release. However, some 
studies indicate that PLGA NPs larger than 100 nm would be safer for biomedical applications 
[47]. Another drawback of these polymeric NPs is the challenge of hydrophilic drugs 
entrapment, since those drugs rapidly partition into the aqueous phase during NPs 
preparation. For that is necessary to use appropriate preparation methods as the double 
emulsion technique [5]. Finally, it is essential to functionalize the NP surface in order to 
achieve a maximum efficacy [24]. 
 
2.3 Vitamin D3 and its application in chemotherapy  
 
Vitamin D, a seco-steroid hormone, is known as an important regulator of calcium 
homeostasis and bone mineralization [48-50]. However, in the late 1970s Vitamin D was found 
Drug  
Surface  
funcionalization 
Indication Development phase Trade name 
Pharmaceutical  
Company 
References 
Docetaxel  PEG Various cancers Phase I clinical trial BIND-014 BIND Bioscience [18] 
FX005 - 
Treatment of Pain in  
Osteoarthritis of the Knee 
Phase II of clinical trial  
completed 
FX005-PLGA PharmaNet Sp. [36] 
Benzocaine  - Pain relief In vitro studies - - [37] 
Cisplatin PMSA Prostate cancer In vitro  studies - - [38] 
Dexamethasone - Arthritis and osteoarthritis In vitro  studies - - [39] 
Doxorubicin - Various cancers Animal studies (rats) - - [40] 
Etoposide - Various cancers 
Animal studies (mice and  
rabbits) - 
- [41] 
Gentamycin - Brucellosis Animal studies (mice) - - [42] 
Insulin - Diabetes Animal studies (rats) - - [43] 
Paclitaxel PEG Liver tumor Animal studies (mice) - - [44] 
Rapamycin EGFR Breast Cancer In vitro  studies - - [45] 
Rifampicin -  Tuberculosis Animal studies (mice) - - [46] 
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in tissues not previously considered targets of vitamin D action, which came to disclose that 
this hormone may carry out several other functions, namely antineoplastic activity [51]. In 
humans’ bloodstream, Vitamin D displays two main chemical forms: D2 or ergocalciferol, and 
D3 or cholecalciferol [52]. The first one comes from dietary source and the latter is produced in 
the epidermis from the action of sunlight and represents 95% of total blood’s Vitamin D [52]. 
These two forms exhibit chemical differences in their side chains. As it is shown in figure 7, D2 
has an extra methyl group at C24 and an extra double bond between C22 and C23. These 
structural changes, between D2 and D3, are reflected in their affinity for the carrier known as 
vitamin D binding protein (DBP). Despite their metabolites’ biologic activity is comparable, the 
fact that Vitamin D3 has a higher affinity for DBP leads to the observation that in humans 
vitamin D3 potency is three times higher than vitamin D2’s [53-55]. In fact, all evidence 
reported to date on the efficacy of vitamin D for cancer prevention has been based on vitamin 
D3 [56]. For that reason only Vitamin D3 will be covered for the next sections of this assay.  
 
Figure 7 | Chemical structures of (A) Cholecalciferol and (B) Ergocalciferol  [51]. 
 
Depending on its degree of hydroxylation, Vitamin D3 can be found with three different 
chemical structures: Calciol, Calcidiol (25-OH-D3) and Calcitriol (1,25-(OH)2D3). Cholecalciferol 
(Calciol) is inert and must be metabolized in the liver and the kidney through two 
hydroxylation processes to be converted to its active form, calcitriol [4]. In figure 8 it’s 
schematized the structural formulas and the overall process of Vitamin D activation.
 
Figure 8 | Representation of Vitamin D3 three different chemical structures: (A) Calciol; (B) Calcidiol; (C) Calcitriol. 
This scheme also represents the overall chemical reactions involved in the activation of Vitamin D [53].  
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Despite its well-known regulation of calcium homeostasis and bone mineralization 
functions, calcitriol is nowadays associated with many additional activities including anti-
proliferative, pro-differentiating, anti-inflammatory, and immunomodulatory effects. For 
example, this hormone has the ability to suppress prostaglandin actions and enhance pro-
inflammatory cytokines production, displaying a role in ceasing inflammatory process [57].  In 
figure 9 is summarized the vitamin’s metabolism, as also calcitriol role in many biological 
functions [58].  
 
  
Figure 9 | Representation for epidermal synthesis of cholecalciferol, its metabolism and a multitude of its several 
potential physiological activities [58]. 
 
Several studies support that Vitamin D also plays a major role in tumor’s pathogenesis, 
progression and therapy [3, 57, 59, 60] and the antineoplastic activity of calcitriol in pancreatic cancer 
is well established, as several in vitro and in vivo studies have been reported  [61-64]. Calcitriol acts like 
classical steroid hormones, binding to vitamin D receptor (VDR) and targeting gene expression via both 
genomic and non-genomic pathways [3]. This receptor is widely distributed among tumor cells, 
regulating calcitriol antineoplastic activity [53, 57, 60]. Therefore several pathways by which vitamin D 
metabolites may prevent, treat or stop tumor growth have been described. The most discussed 
mechanisms are: (1) inhibition of tumor cell growth; (2) inhibition of angiogenesis and tumor 
metastasis; (3) triggering apoptosis; (4) enhancing “traditional” anticancer agents therapeutic action; 
(5) anti-inflammatory effects [3, 57, 59, 60]. A more detailed explanation about these mechanisms is 
presented below. 
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(1) VDR activation by calcitriol can inhibit tumor cell proliferation by inducing cell cycle 
arrest in the G1/G0 phase [3, 57, 59] or through inducing malignant cells differentiation 
in a variety of cell lines [57, 59, 60]. Calcitriol up-regulates the expression of the cell 
cycle inhibitors p21 and p27 leading to cell cycle arrest prior to DNA replication in S 
phase essential to cell division [65]. 
(2) Calcitriol also inhibits angiogenesis by reducing the proliferation of vascular 
endothelial cells [57, 59] and regulating the expression of key molecules, such as 
serine proteinases, metalloproteinases, extracellular matrix proteins and integrins [57, 
60]. Another calcitriol antineoplastic activity is related to reducing the invasive and 
metastatic potential of tumor cells [3, 57, 60]. Inhibition of tumor metastasis is due to 
increased expression of E-cadherin, a tumor suppressor associated with the metastatic 
potential of cells, and inhibition of angiogenesis itself [60].  
(3) Apoptosis triggering of tumor cells occurs through activation of the intrinsic pathway 
of apoptosis by increasing the expression of pro-apoptotic proteins and decrease the 
expression of anti-apoptotic proteins, or by directly activate effector caspases [3, 59]. 
Apoptosis may also be induced by inhibition of telomerase enzyme [59]. This 
programmed cell death is characterized by causing the disruption of mitochondrial 
function, cytochrome release and production of reactive oxygen species [3, 59]. 
(4) Vitamin D can also potentiate the antitumor actions of a number of more “traditional” 
anticancer agents [57, 59]. 
(5) Inflammatory mediators such as cytokines, chemokines, prostaglandins, and reactive 
oxygen and nitrogen species enhance tumorigenesis through the activation of multiple 
signaling pathways in tumor tissue. Hence, anti-inflammatory effect of calcitriol 
mentioned at the section above can be also considered as an antineoplastic activity [3, 
57]. 
 
2.3.1 Nanoparticles as carrier for  Vitamin D 
 
Despite calcitriol’s multiple medicinal benefits, its low bioavailability and high toxicity 
continue to be highlighted as major challenges in developing formulations for clinical use. In 
fact, two pharmaceutical formulations for Rocaltrol® (registered trademark of Roche 
Pharmaceuticals) are available with different administration pathways, oral and intravenous, 
for the treatment of refractory malignancies. However, they are inappropriate for cancer 
treatment due to several technical issues, as the difficulty to maintain active systemic levels 
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[66, 67]. To overcome some of these limitations, drug delivery systems can be envisaged for 
new calcitriol formulations. Although several studies, among Vitamin D3 encapsulation for food 
fortification, have been conducted, the use of nanocarriers for Vitamin D3 delivery towards 
cancer treatment was only report three times. Two works intended Vitamin D3 vectorisation in 
order to ensure specific action on malignant cells avoiding side effects as hypercalcemia. For 
that purpose, Nguyen and colleagues (2007) developed a formulation based on poly(vinyl 
neodecanoatecrosslinked-ethyleneglycol dimethacrylate) microspheres, with a size of 
approximately 35 μm. In this project cholecalciferol was used as a model drug for calcitriol. 
Nguyen and co-workers demonstrated that their cholecalciferol-loaded microspheres are 
biocompatible, allow controlled and sustained release and increase the efficiency of the 
therapy [68]. A few years later, Almouazen and partners (2012) developed a formulation using 
PLA nanoparticles with approximately 200 nm. This study proved that PLA nanocapsules are a 
suitable choice for controlled delivery of antineoplastic agents. Almouazen and co-workers 
also concluded that nanoencapsulated calcidiol induced a significant growth inhibition when 
compared to free calcidiol, and also that PLA NPs are able to enhance the intracellular delivery 
of vitamin on breast cancer [66]. Lastly, Bonor and co-workers (2012) developed calcitriol 
conjugated quantum dots (QD) to analyze calcitriol distribution and dynamics in mouse 
myoblast cell line. According to their conclusion, QD can be used for imaging drug-tumor 
interactions and to deliver drugs to tumors and metastasized sites [69]. 
Vitamin D3 encapsulation in PLGA NPs, as intended in this work, should increase 
calcitriol bioavailability and reduce its toxicity. Several studies indicate that more than 75% of 
Vitamin D intake is catabolized and excreted before being converted to its active form or 
before its storage [52]. This fact could be a good reason to the use of NPs as drug delivery 
systems. Since these systems will prevent vitamin D elimination before the appropriate time, 
increasing vitamin’s bioavailability. Vitamin D entrapment in PLGA NPs will also avoid first-pass 
effect suffered by orally ingested vitamin. After being absorbed by the intestinal mucosa, 
vitamin D is conducted by the portal vein to the liver where it is metabolized. Hepatic 24-
hydroxylase enzyme inactivates calcitriol by hydroxylation. Therefore, vitamin D concentration 
is greatly reduced before it reaches the systemic circulation, and consequently reaches target 
tissues [70]. However, Vitamin D encapsulation in PLGA NPs could inhibit this degradation.  
Also should allow circumventing the multi-drug resistance (MDR) problem [30]. In addition to 
increasing the bioavailability, functionalization of PLGA NPs surface allow vitamin D 
vectorisation. This ensures specific action on cancer cells and increases the concentration 
delivered while avoiding side effects [6]. This specific-tissue targeting avoids hypercalcemia 
toxicity’s phenomena. Calcitriol has anti-tumoral activity in supraphysiological dose (10−9 to 
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10−6 M in vitro and >10−9 M in vivo) associated with a high risk of hypercalcemia [60, 66].  
Finally, the characteristic drug release pattern already mentioned of this kind of NPs is a major 
advantage. PLGA NPs allow maintaining a controlled and sustained release of drugs. As in 
cancer, it is advantageous to have slow doses for long periods of time these NPs are a suitable 
choice, enhancing therapeutic efficiency. Low doses are related to less side-effect to healthy 
tissues. And also, sustained release allows diminishing the administration frequency since it 
allows maintaining active doses for longer periods of time [4].  
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3 MATERIALS AND METHODS 
3.1 Materials 
PLGA Resomer® RG503H (50:50; MW 24.000 – 38.000), ethyl acetate, Pluronic® F127 
and phosphate buffered saline (PBS) were purchased from Sigma–Aldrich (St. Louis, Mo., 
U.S.A). Two aqueous solutions of 0.1% and 1%(w/v) Pluronic F127, respectively, were 
prepared. Cholecalciferol (Vitamin D3, MW 384.65, purity ≥ 99%) was purchased from Alfa 
Aeasar (Karlsruhe, Germany). Calcitriol (Rocaltrol, MW 416.64, purity ≥ 99%) was purchased 
from Selleck Chemicals (Munich, Germany) and was reconstituted in 100% ethyl acetate and 
stored at -20 ºC. Ethanol [purity ≥ 99.9% (v/v)] was purchased from Carlo Erba Reagents (Val 
de Reuil, France). For TEM sample preparation, uranyl acetate (dehydrate, 424.146 g/mol) was 
purchased from Electron Microscopy Sciences (Hatfield, UK). For cytotoxicity assays, 
Dulbecco's Modified Eagle medium (DMEM) was obtained from Invitrogen Co. (Scotland, UK). 
Acetic acid, dimethyl sulfoxide (DMSO), sulforhodamine B (SRB) and trypan blue were 
purchased from Sigma-Aldrich (Germany). Tricloroacetic acid (TCA) and Tris buffer were 
acquired from Merck (Darmstadt, Germany). All aqueous solutions were prepared in deionized 
and filtered ultrapure Milli-Q water (Milli-Q Academic, Millipore, France). 
 
3.2 Methods 
3.2.1 PLGA nanoparticles preparation 
 
PLGA NPs were prepared using the emulsion-solvent evaporation technique. There are 
two modifications of this process, the single and double emulsion. The choice depends upon 
the hydrophilicity of the drug to be encapsulated. As Vitamin D3 metabolites are hydrophobic 
molecules, a single emulsion process was used [5, 31, 32]. For that purpose, 100 µL solution of 
100 mg/mL of PLGA in ethyl acetate was prepared, and for encapsulation purpose 1 mg of 
vitamin was added. 200 μL of an aqueous solution of 1% (w/v) pluronic F127 was added 
dropwise to the organic phase (PLGA and vitamin dissolved in ethyl acetate). Then, the 
moisture was vortexed (Genius 3, ika®vortex, Germany) and emulsified by sonication at an 
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ultrasonic frequency of 45 kHz in a beaker with ice using Ultrasonic cleaner (VWRTM, Malasya). 
Typically, stirring of the emulsion originates microdroplets. In order to induce the nanosized 
droplets, sonication process was carried out. The size reduction is induced through a two-step 
mechanism. Firstly, applying acoustic waves through the water creates interfacial waves and 
instability which causes the eruption of the oil phase into the water medium in the form of 
droplets. Secondly, applying low frequency ultrasound causes acoustic cavitation, that is, the 
formation and subsequent collapse of microbubbles, leading to turbulence. This turbulence 
breaks up the primary droplets of dispersed oil into nanosized droplets [71, 72]. 
After emulsification was completed, the emulsion was poured very fast into 2.5 mL of 
0.1% (w/v) pluronic F127 and stirred (800 rpm) at room temperature for 3 hours in order to 
completely evaporate the organic solvent, using Colorsquid (ika®) magnetic stirrer. It is 
important to note that, this transfer step must be completed very quickly, in order to avoid 
PLGA NPs aggregation before being stabilized by the surfactant. The evaporation step was 
performed in a flow chamber Captair®bio from Erlab (Barcelona, Spain). Evaporation of the 
solvent transforms droplets of dispersed phase into solid particles [73]. 
The resulting suspension was filtered with Millex-GP Filter Units (0.2 μm, 
polyethersulfone) (Millipore Express, Ireland) and incubated at 4 ºC overnight to avoid NPs 
aggregation and increase their stability.  Then the NPs were collected by centrifugation (14500 
rpm, 30 min) with MiniSpin®plus (Eppendorf, Germany), and the pellet was resuspended in 1 
mL of ultrapure water. The supernatant was also saved for analysis.    
Two experimental parameters, the sonication step and the vitamin/polymer ratio, 
were tested in order to achieve the adequate experimental conditions. For sonication time, 1, 
5 and 10 minutes were evaluated. Also, 1% and 10% (w/w) of vitamin were tested. Due to the 
cost of calcitriol, the inactive form of vitamin D3, cholecalciferol, was used as drug model in this 
step. All formulations were prepared in triplicate. 
In this described process, the drug is incorporated during the NP production. However, 
the drug could be adsorbed on the NP after its production [32].  
 
3.2.2 PLGA Nanoparticles physicochemical characterization  
 
The size, polydispersity index, zeta potential, morphological appearance and drug-
loading capacity were the parameters used to characterize the produced nanoparticles. The 
effect of process parameters on nanoparticles properties was assessed, including different 
times of sonication and the vitamin/polymer ratio.  
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3.2.2.1 Nanoparticles size 
 
Dynamic Light Scattering (DLS) is a well known technique to determine the size of 
nanoparticles in dispersion or solution. When a light beam hits on a NP, part of the incident 
light is scattered. As NPs in suspension are in constant movement due to Brownian motions, 
they lead to changes in scattered light intensity. Then, DLS can provide information about the 
average size and size distribution of a NP in suspension, by measuring the fluctuations of 
scattered light intensity as a function of time. The rate of change of scattered light is directly 
proportional to the movement of the particles and can be related to their diffusion coefficient. 
Then, NPs size can be calculated from the diffusion coefficient  , using Stokes-Einstein 
equation [74, 75]: 
                                                           
  
    
                                                                         (1) 
where, RH is the hydrodynamic radius; k, the Boltzmann constant; T, temperature; η, the 
viscosity of the solvent. 
In addition to the size, DLS also allows determining the polydispersity index (PdI). PdI is 
an indicative of the heterogeneity of NPs sizes in a suspension [75]. For a near-monodisperse 
sample, a PDI of 0.1 or lower is expected [76]. The presence of aggregates can distort the 
results, since the equipment analyzes them as a large size single particle, resulting in higher 
PdIs [77]. 
In this work, DLS measurements were performed using a ZetaSizer Nano ZS (Malvern 
Instruments, Worcestershire, UK). The size distribution was given by PdI. All the 
determinations were performed in disposable cells (Sarstedt, Germany) and using water as 
dispersant medium. Mean values for each preparation were obtained by triplicate 
measurements. Each measurement was performed with 12 runs. 
 
3.2.2.2 Zeta Potential 
 
Electrophoretic light scattering (ELS), also known as Laser Doppler Micro-
electrophoresis, is used to evaluate the zeta potential (ζ –potential), a key parameter that 
controls electrostatic interactions between particles in a dispersion and therefore its stability 
[78]. Particles in a suspension attract ions to their surface. These ions form an electrical double 
layer covering the particle surface. This double layer comprises an inner layer, the Stern layer 
where counterions are strongly adsorbed; and an outer layer, where ions diffuse more freely. 
This diffuse layer terminates the boundary of the particle as a single charged entity and the 
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electric potential that exists at this boundary is called the zeta potential. Particles with very 
positive/negative ζ –potential will repel each other and resist to aggregation. On the contrary, 
low absolute zeta potential values results in aggregation and flocculation [79]. A physically 
stable nanosuspension will have a minimum zeta potential of absolute value of 30 mV [31]. 
When an electric field is applied, electrophoresis occurs and ELS measures the velocity 
of the charged particles [78]. Electrophoretic mobility (μ) is given by the following equation 
[80]: 
                                                                              
 
 
                                                          (2) 
where, v is the velocity; and E,  the applied electric field.  
Then, Henry’s Law allows to calculate ζ-potential [78]: 
                                                                                      
        
  
                                                       (3) 
where μ is the eletrophoretic mobility; ε, the dielectric constant of the dispersant; ζ, the zeta-
potential; F(ka), is the Henry function; and η, the viscosity coefficient. 
Usually the laboratory equipments incorporate several techniques in a single compact 
unit. In fact, in this work ZetaSizer Nano ZS also provided measurements of zeta potencial by 
ELS. It was used folded capillary cells from Malvern (Worcestershire, UK) and the dispersant 
medium was water. Mean values for each preparation were obtained by triplicate 
measurements. Each measurement was performed with 12 runs. 
 
3.2.2.3 Morphologic analysis  
 
Transmission electron microscopy (TEM) is one of the most efficient and versatile tools 
for the characterization of nanomaterials morphology. This technique has much higher 
resolution than conventional light microscopy and is based on the interaction of an electron 
beam with the sample through which it passes. When the beam hits the sample, electrons 
interact with the matter, and part of them is transmitted through the sample. These 
transmitted electrons are focused to a phosphor screen at the bottom of the microscope 
where the image is formed. The beam that reaches the phosphor screen consisted of different 
amounts of electrons that pass through particular regions of the sample. This difference is 
responsible for the image contrast. Darker areas of the image represent the regions of the 
sample through which fewer electrons were transmitted, due to the greater thickness or 
density. Contrariwise, brighter areas are the result of increased electronic transmission 
through the sample, i.e. representing thin regions of the sample [81, 82]. 
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The morphological examination of the NPs was performed by TEM Yeol Yem 1400 at 
an accelerating voltage of 80kV (Tokyo, Japan). For that purpose, the samples were prepared 
with negative staining. 10 μL samples were stained with 2% (v/v) uranyl acetate for 45 
seconds, immobilized on copper grids (Formvar/Carbon on 400 mesh Cu (50) from Agar 
Scientific), and air-dried for TEM visualization [83]. TEM samples must be prepared in order to 
improve their visualization. Uranyl acetate is a heavy metal salt capable of scattering electrons, 
and therefore enhancing the image contrast [84]. 
 
3.2.2.4 Nanoparticles loading capacity 
 
Cholecalciferol and calcitriol loading capacity (LC) of PLGA NPs was calculated by the 
following equation: 
 
 
    
                                          
                   
       
 
(4) 
              Loading capacity was determined indirectly. Therefore, the quantity of drug entrapped 
in the NPs was calculated by the difference between the total drug dissolved in ethyl acetate 
during NPs preparation and the quantity of non-entrapped vitamin remaining in the aqueous 
suspending medium. For the quantification of the free cholecalciferol and calcitriol, the NPs 
suspension was centrifuged (14500 rpm, 30 min), and the supernatant analyzed. The sample 
was measured by UV-Vis spectrophotometry at 265 nm, using a UV-1700 PharmaSpec UV-Vis 
spectrophotometer from Shimadzu (Japan). The results were correlated to a calibration curve 
for which vitamin form in 3.5% of ethyl acetate in an aqueous solution of 0.1% pluronic 
(Appendix A and B– figures 17 and 18). This step was conducted before organic solvent 
evaporation in order to ensure vitamin solubility. All experiments were performed in triplicate.  
 
3.2.3 Determination of encapsulation efficiency 
 
The quantification of cholecalciferol and calcitriol entrapped in the NPs was conducted 
as previously described in section 3.2.2.4. All experiments were performed in triplicate. 
Encapsulation efficiency (EE) of PLGA NPs was calculated by the following equation: 
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(5) 
3.2.4 Determination of Process Yield 
 
For the determination of the NPs production yield, the difference between the used 
polymer mass for the NPs preparation and the actual dried NPs weights were obtained. All 
experiments were performed in triplicate. The yield of the process was calculated by the 
following equation: 
 
 
                  
                         
            
       
 
(6) 
The unloaded NPs weight was determined by gravimetry following a procedure 
adapted from Grenha and co-workers [83]. The NPs suspension was centrifuged (14500 rpm, 
30 min). The pellet NPs were resuspended in 200 µL of deionized water and the supernatant 
was discarded. The pellet was dried overnight, and the final mass of the NPs was measured. All 
experiments were performed in triplicate. 
 
3.2.5 NPs stability studies 
 
In order to evaluate the PLGA NPs stability, PLGA NPs’ dispersions in ultrapure water 
were stored at 4 °C. These tests were performed in both formulations; cholecalciferol-loaded 
and calcitriol-loaded NPs. DLS and ELS measurements were performed to evaluate 
modifications in PLGA NPs size and zeta potential. These measurements were performed every 
week, over a period of nine weeks.  
The drug-loaded PLGA NPs were re-suspended in ultrapure water (200 µg.mL-1) into an 
eppendorf semi-capped to allow gas output during freeze-drying process. Samples were frozen 
at −20 °C for 3 hours and then lyophilization was carried out in a BenchTopTM K series freeze-
drier from VirTis® (NY, USA) at 5 x 10-5 Bar and – 95 oC for 48 hours. The freeze-dried samples 
were sealed and stored at 4 °C before analysis. The samples were then reconstituted within a 
day using the same initial volume (1 mL) of ultrapure water. Mean size variation and particle 
aggregation was quantified by DLS analysis. After the lyophilized cake hydration, the vitamin D 
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stability analysis was also performed by UV-Vis spectrophotometry measurements. All 
formulations were prepared in triplicate. 
The effect of sucrose as a cryoprotective agent on the NPs stability during freeze-
drying was also determined. The cryoprotectant was added to the drug-loaded PLGA NPs 
suspension before freezing at the concentration of 1% (w/v). All experiments were performed 
in triplicate. 
 
3.2.6 In vitro release studies 
 
In vitro release behavior of calcitriol entrapped in the PLGA NPs were assessed using a 
modified centrifugation method [85] over seven days. A sufficient amount of calcitriol-loaded 
PLGA NPs were re-suspended in release buffer (PBS 0.01 M, pH 7.4) and divided in 7 aliquots. 
The aliquots were maintained in a water bath at 37 °C in a drying oven (Venti-line, VWR, 
Belgium). At determined set time points, each aliquot was withdrawn from the water bath and 
centrifuged at 14400 rpm for 10 min. Amicon® Ultra-0.5 centrifugal filter devices (Millipore, 
County Cork, Ireland) were used in order to remove PLGA degradation products and NPs and 
then the release medium was freeze-dried. The lyophilized samples were further reconstituted 
with ethanol 100% (v/v) for measurement by UV-Vis spectrophotometry at 265 nm. The results 
were correlated to a calibration curve in ethanol (Appendix B – figure 19). The calcitriol release 
curve, representing the percentage of drug released in function of time, was then drawn by 
the following equation:  
 
 
                
                                 
                           
       
 
(7) 
 
3.2.7 Cell lines 
 
The two human pancreatic cell lines studied, T-HPNE (hTERT immortalized Human 
Pancreatic Nestin-Expressing normal ductal-derived epithelial cells) and S2-013 (well 
differentiated tubular adenocarcinoma and moderately metastatic subline cloned from the 
human pancreatic tumor cell line SUIT-2), were kindly provided by Prof. M. A. Hollingsworth 
(Eppley Institute for Research in Cancer and Allied Diseases, UNMC, Omaha, NE, USA)  [86, 87]. 
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For cell culture proposes, both cell lines were maintained in DMEM medium, supplemented 
with 10% fetal bovine serum (FBS) at 37 °C in a humidified 5% CO2 incubator. When the cells 
reached 80% of confluence, they were trypsinized and subcultured.  
3.2.8 In vitro cytotoxicity studies  
 
The effects of the calcitriol-loaded PLGA nanoparticles and free calcitriol, on the cell 
growth and survival in pancreatic cell lines, were evaluated using Sulforhodamine B (SRB) 
assay. SBR assay is a colorimetric, sensitive, nondestructive, rapid and inexpensive assay that is 
used for the in vitro measurement of cellular protein content [88, 89]. Sulforhodamine B is an 
anionic bright pink aminoxanthene protein dye with two sulfonic groups [89]. SBR binds to 
basic amino acids of proteins of TCA-fixed cells. The colorimetric evaluation provides an 
estimate total protein mass, which is related to cell number and therefore related to cell 
survival and viability [88-90]. 
Experiments were performed in 96-well assay plates, where exponentially growing 
cells were seeded for an incubation period of 24 hours at a density of 1000 cells per well 
before treatment with free calcitriol, blank PLGA NPs and calcitriol-loaded PLGA NPs. This 
incubation period under normal conditions (5% CO2 humidified atmosphere at 37 ºC) allows 
cell to adhere. The samples of NPs and free calcitriol were diluted in DMEM at eight final 
concentrations of calcitriol ranging from 5 to 2500 nM, and the cells were incubated with 
these samples for 48 h and 72 h, respectively. A calcitriol stock solution of 2.4 mM was 
prepared in ethanol to ensure calcitriol solubility in culture medium. However all samples of 
calcitriol alone contained at most 0.1% (v/v) ethanol. Due to the short half-life of calcitriol, the 
supplemented medium was renewed daily. After the 48–72 hours incubation period, the 
cytotoxic effect was assayed by SRB, using a well described methodology established by 
Skehan and colleagues (1990) [91]. The cells were fixated with 10% TCA for 1 hour on ice. After 
the incubation period the cell monolayers were washed and stained with 50 µL SRB dye for 30 
minutes. The cells were then washed repeatedly with 1% acetic acid to remove unbound dye. 
The cells air-dried and the protein-bound stain was solubilised with 10 mM Tris solution. The 
SRB absorbance was measured at 560 nm using the PowerWave microplate reader (HT 
Microplate Spectrophotometer, BioTek).  
The absorbance of the wells after incubation period were analyzed and compared by 
the following equations [92]: 
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 as measure of cell viability and survival in the presence of calcitriol-loaded PLGA NPs 
and free calcitriol: 
                                                              
 
 
                                                        (8) 
 as measure for growth inhibition in the presence of calcitriol-loaded PLGA NPs and 
free calcitriol:                                        
                                                       
      
      
                                                 (9) 
where T is the quantitative measurement (absorbance value) at the end of the incubation 
period in the wells containing loaded PLGA NP or free calcitriol, T0 is the quantitative 
measurement at the time of test drug addition and C is the quantitative measurement in the 
control wells (untreated cells). Therefore, concentration-response curves using non-linear 
regression analysis were obtained and the concentration inhibiting cell survival by 50% (IC50), 
together with the concentration inhibiting the net cell growth by 50% (GI50) were determined. 
IC50 and GI50 are the concentrations of test drug where the following equations, respectively, 
are applicable [92]: 
                                                                    For IC50    
 
 
                                               (10) 
                                                                 For GI50:   
      
      
         %                                (11) 
  
Bare PLGA NPs and 0.1% ethanol were added as control to assess if they will affect cell 
survival in control cells. Also, not exposed cells were also included in all assays as no-treatment 
controls (null controls) and all samples were tested in triplicates. 
 
3.2.9 Statistical analysis 
 
Statistical analysis was performed by using two-tailed Student’s t-test, considering a 
confidence interval of 95%. P-values lower than 0.05 were considered significant. 
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4. RESULTS AND DISCUSSION 
4.1 Physicochemical characterization of PLGA nanoparticles 
 
PLGA NPs were prepared by a single emulsion solvent evaporation method and 
stabilized with Pluronic F127. Sonication of the emulsion is a crucial step to define the size of 
the nanoparticles. As stirring of the emulsion originates microdroplets, sonication process 
allows size reduction to nanoscale [71]. The influence of the sonication time was evaluated 
and the physicochemical properties of the produced unloaded PLGA NPs are presented in table 
4.  
Table 4 | Effect of sonication time on the physicochemical properties of the produced bare PLGA NPs. Data 
represented as mean ± SD (n=3).  
  Sonication time Mean diameter (nm) PdI Zeta potential (mV) 
Bare  
PLGA NPs 
1 min 176 ± 2 0.096 ± 0.090 - 34 ± 4 
   
5 min 172 ± 4 0.064 ± 0.040 - 38 ± 3 
 
10 min 173 ± 18 0.054 ± 0.027 - 36 ± 3 
 
Typically, according to the literature, PLGA NPs size is founded to be in the range of 
100 to 250 nm [32]. The unloaded NPs, produced with three different sonication times, 
exhibited mean sizes varying between 172 and 176 nm. It was concluded that with increased 
sonication time, mean sizes were not significantly different (P>0.05) and are within the 
expected range. Also, no significant changes were verified (P>0.05) for PdI and zeta potential 
values. The sonication time selected for the following experiments was 5 minutes. 
The single emulsion solvent evaporation method allowed the encapsulation of vitamin 
D3 in the PLGA NPs. The attained results for mean diameter, PdI, zeta potential, encapsulation 
efficiency and loading capacity values for the PLGA NPs loaded with cholecalciferol and 
calcitriol are shown in table 5.  
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Table 5 | Physicochemical features of cholecalciferol and calcitriol-loaded PLGA NPs. Data represented as mean ± 
SD (n=3). 
  
Vitamin D 
/polymer ratio 
Mean 
diameter (nm) 
PdI 
Zeta potential 
(mV) 
EE (%) LC (%) 
Cholecalciferol-
loaded PLGA NPs 
1% 172 ± 8 0.069 ± 0.033 - 33 ± 1 81 ±  17 0.8 ± 0.1 
      
10% 185 ± 6 0.133 ± 0.060 - 29 ± 4 83 ± 2 8.3 ± 0.2 
 
Calcitriol-loaded 
PLGA NPs 
10% 185 ± 4 0.052 ± 0.040 - 31 ± 1 57 ± 8 5.7 ± 0.9 
 
 
 
As it can be concluded after the analysis of table 5, the mean diameters of the loaded 
PLGA NPs ranged from 172 to 185 nm. That is, they were according to the expected values. As 
it is also shown in tables 4 and 5, 10% drug-loaded NPs exhibited a significantly larger size than 
unloaded PLGA NPs (P≤0.05), regardless of whether it was encapsulated cholecalciferol or 
calcitriol. The size increased from 172 (± 4) to 185 (± 6) nm and 185 (± 4), respectively. This 
effect was reported in studies that argue that the drug causes an expansion of the polymeric 
matrix, increasing particle size [93]. This matrix expansion also explains the significant increase 
(P≤0.05) of the NP diameter as the choelcalciferol/polymer ratio increases, from 172 (± 8) in 
1% cholecalciferol to 185 (± 6) nm in 10% cholecalciferol. Moreover, mean size values were not 
significantly different for both 10% cholecalciferol and 10% calcitriol-loaded NPs (P>0.05). The 
prepared systems exhibited a narrow size distribution (PdI ≤ 0.1). 
Zeta potential values for PLGA NPs are negative as expected, ranging from -38 to -29 
mV, due to their carboxylic end-groups, as it is shown in tables 4 and 5. Zeta potential absolute 
value significantly decreased from 38 in unloaded PLGA NPs to 29 and 31 mV in 10% 
cholecalciferol-loaded and6 10% calcitriol-loaded NPs, respectively (P≤0.05). These values 
could be explained by Vitamin D adsorption on PLGA NPs surface. As already reported by 
Musumeci and colleagues, the drug adsorbed on PLGA NPs surface exert a masking effect of 
the superficial carboxylic groups, reducing the effective NP charge [93]. This masking effect 
could also explain the decrease, although not significant (P>0.05), in zeta potential values 
when cholecalciferol proportion increased from 1 to 10%, since more available vitamin D may 
led to a greater adsorption at NPs surface. Moreover, zeta potential values were not 
significantly different for both 10% cholecalciferol and 10% calcitriol-loaded NPs (P>0.05). NPs’ 
stability is a result of static stabilization, i.e., electrostatic forces due to the PLGA carboxylate 
groups at the NP surface, and the surfactant behavior that also plays a crucial role in 
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B 
maintaining nanosuspension stabilization. During particle formation, the stabilizer is able to 
modify NPs stabilization [59] by adsorbing onto the NP surface [63]. In fact, in figure 10, a 
morphologic examination performed by TEM shows a pluronic layer surrounding PLGA NPs. 
The surfactant causes steric repulsions forming a mechanic barrier prohibiting droplet 
approaching. Thermodynamic stabilization can also be considered, due to a loss of 
configurational entropy of surface adsorbed pluronic when overlapping occurs for approaching 
droplets [14].  For all those reasons, it can be concluded that the method followed for the 
preparation of PLGA NPs produced well-stabilized monodisperse nanoparticles. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10 | Transmission electron microscopy images of the: (A) unloaded PLGA nanospheres- the scale bar 
corresponds to 200 nm; (B) loaded PLGA nanospheres- the scale bar corresponds to 500 nm. The red arrow 
indicates the pluronic layer surrounding the PLGA NP. 
 
Additionally, TEM analysis of PLGA nanoparticles revealed spherical and uniform 
shaped nanoparticles, as it is shown in figure 10. The diameter of the nanoparticles revealed 
by this method changes between approximately 170 and 190 nm, which is in conformity with 
the size measurement by DLS. These images also show a relatively monodisperse 
nanoparticles.  
The obtained results for encapsulation efficiency for both encapsulated forms of 
Vitamin D3 are expressed in percentages in table 5. EE values achieved are according to our 
experience with other hydrophobic drugs [85] and other results reported in literature that 
state that EE values for PLGA NPs may vary from 6 to 90% [32]. One reason for not having 
reached the higher values may be related to vitamin solubility in the surfactant solution [31]. 
As already reported in other studies, drugs can be incorporated into the core of the micelles 
formed by Pluronic [34]. As table 5 shows, no significant changes of EE values (P>0.05) were 
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observed for the different cholecalciferol/polymer ratios reported. However for 10% ratios, 
the attained values significantly decreased (P≤0.05) for the active form of Vitamin D3, from 83 
± 2% for cholecalciferol to 57 ± 8% for calcitriol. This was already reported by Almouazen and 
colleagues (2012) [66] and can be explained by cholecalciferol highest hydrophobicity. As 
calcitriol is less hydrophobic due to the two extra hydroxyl groups, its partition into the 
aqueous phase may occur during the NPs preparation, resulting in lower EE values.  
The cholecalciferol loading capacity of PLGA NPs was also evaluated. As expected, 
loading capacity values increased significantly (P≤0.05) with the used cholecalciferol/polymer 
ratio (table 5). Moreover, the produced PLGA NPs, with 10% vitamin/polymer ratio, exhibited 
significant differences in the determined loading capacity values (P≤0.05). As table 5 shows, 
cholecalciferol-loaded NPs exhibited a loading capacity of 8.3 ± 0.2%, and the NPs loaded with 
calcitriol have a loading of 5.7 ± 0.9%. This was already expected due to the decreased 
encapsulation efficiency values for the active form. PLGA NPs normally exhibit poor loading 
capacity [32]. Thus, the values obtained in this experimental work are supported by the ones 
found in the literature as also by our experience with other hydrophobic drugs [85]. 
The yield of this PLGA NPs production process is quite satisfactory with values of 57 ± 
4% (n=3). 
 
 
4.2 PLGA NPs stability  
4.2.1 PLGA NPs stability in liquid phase 
 
Mean diameter, PdI and zeta potential values measured for the purpose of stability 
tests are presented in table 6. Mean size variation is expressed in terms of ratio St/Si. 
Cholecalciferol-loaded NPs exhibited a mean St/Si value of 1.031 for approximately 50 days, 
while calcitriol-loaded presented a value of 1.003. Cholecalciferol- and calcitriol-loaded PLGA 
NPs showed mean sizes of 199 ± 1 nm and 190 ± 3 nm, respectively, which have remained 
constant over time. These data proves that the NPs remained physically stable at storage 
conditions (4 oC) for approximately 50 days.   
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Table 6 |Zeta potential, mean diameter and PdI values for both cholecalciferol and calcitriol-loaded PLGA NPs, over 
a period 60 days, respectively. Mean size variation is expressed in terms of ratio St/Si, where Sf is mean diameter 
after t days of storage and Si is the NPs initial mean size. Data represented as mean ± SD (n=3). These data is only 
relative to one batch for each formulation, loaded and unloaded.  
PLGA NPs 
Mean diameter 
(nm) 
Ratio St/Si PdI 
Zeta potential 
(mV) 
Cholecalciferol-loaded 
 
 
  
Day 1 199 ± 1 - 0.031 ± 0.014 - 29 ± 1 
Day 7 200 ± 3 1.005 0.019 ± 0.017 - 30 ± 1 
Day 14 199 ± 3 1.000 0.047 ± 0.006 - 25 ± 1 
Day 21 199 ± 5 1.000 0.052 ± 0.016 - 19 ± 1 
Day 28 204 ± 4 1.025 0.068 ± 0.017 - 22 ± 1 
Day 35 206 ± 4 1.035 0.060 ± 0.021 - 25 ± 1 
Day 42 206 ± 5 1.035 0.097 ± 0.020 - 25 ± 5 
Day 49 222 ± 6 1.116 0.191 ± 0.034 - 16 ± 1 
Day 60 546 ± 100 2.744 0.609 ± 0.113 -10 ± 3 
 
 
Calcitriol-loaded 
 
 
  
Day 1 190 ± 3 - 0.114 ± 0.029 - 29 ± 2 
Day 7 188 ± 1 0.989 0.074 ± 0.036 - 30 ± 1 
Day 14 185 ± 1 0.974 0.086 ± 0.030 - 27 ± 1 
Day 21 192 ± 6 1.011 0.089 ± 0.026 - 25 ± 2 
Day 28 194 ± 1 1.021 0.163 ± 0.032 - 28 ± 1 
Day 49 194 ± 6 1.021 0.187 ± 0.052 - 22 ± 3 
Day 60 1189 ± 124 6.258   1.000 ± 0.455 -1 ± 1 
 
Zeta potential values showed a slight increase over time (table 6). However as applying 
an electric field to the sample may alter it, only values for size were considered for stability 
evaluation purposes. 
 
4.2.2 PLGA NPs stability in solid phase 
 
As the previous results show, the PLGA NPs are stable in aqueous medium only for a 
certain period of time. Then it was required to find a strategy that will improve their stability. 
Lyophilization, also known as freeze-drying, is an industrial process which consists on removing 
water from a frozen sample by sublimation and desorption under vacuum. Freeze-drying cycle 
can be divided into three steps: freezing, primary drying and secondary drying. In the first step, 
the liquid suspension is cooled, and ice crystals of pure water forms. Then, the primary drying 
stage involves sublimation of ice; and the secondary stage, involves the removal of unfrozen 
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water [94]. DLS measurements were performed to assess the occurrence of aggregation or 
modification of the PLGA NPs properties after freeze-drying. These data are presented below 
in table 7. 
Table 7 | PLGA NPs physicochemical characterization after freeze-drying experiments, with and without a 
cryoprotective agent. Mean size variation is expressed in terms of ratio Sf/Si, where Sf is mean diameter after 
freeze-drying and Si is the NPs initial mean size. Data represented as mean ± SD (n=3).  
Cholecalciferol-loaded 
PLGA NPs 
Mean diameter (nm) Ratio Sf/Si PdI Zeta potential (mV) 
Before freeze-drying 193 ± 2 - 0.033 ± 0.022 - 28 ± 5 
After freeze-drying 
 
Without cryoprotectants 1573 ± 181 8.108 0.594 ± 0.125 - 27 ± 1 
Sucrose 1% 197 ± 14 1.015 0.152 ± 0.050 - 22 ± 1 
Calcitriol-loaded 
PLGA NPs 
Mean diameter (nm) Ratio Sf/Si PdI Zeta potential (mV) 
Before freeze-drying 186 ± 3 - 0.060 ± 0.010 - 37 ± 2 
After freeze-drying 
 
Without cryoprotectants 1591 ± 167 8.554 0.613 ± 0.369 - 31 ± 1 
Sucrose 1% 193 ± 1 1.038 0.096 ± 0.029 - 29 ± 3 
 
The NP mean diameter and PdI values significantly increased (P≤0.05) after 
lyophilization without cryoprotectant (table 7). As it is proved by the increased PdI values, 
freeze-drying process caused PLGA NPs aggregation yielding a polydispersion. No significant 
changes (P>0.05) were verified for zeta potential values. Hence, it is possible to conclude that 
these PLGA NPs are not able to overcome the stress caused by the lyophilization process 
leading to their destabilization and further aggregation. However, these results also 
demonstrated that 1% sucrose is a cryoprotective agent suitable to preserve particle integrity 
after reconstitution of lyophilised PLGA nanoparticles, yielding no significant changes in mean 
diameter (P>0.05). However, zeta potential values suffer a significant decrease in the presence 
of sucrose (P≤0.05). This could be explained by sucrose adsorption on NPs surface.  The choice 
of sucrose as the cryoprotective agent was justified by a previous work of Holzer and 
colleagues that have proven that this is a well suited cryoprotective agent [95]. The action of 
this agent is essential during the freezing step when a phase separation into ice and cryo-
concentrated solution occurs. The cryo-concentrated phase is composed of nanoparticles, free 
surfactant and unloaded drug. This high concentration of particles induces aggregation. Also, 
the crystallization of ice exercises a mechanical stress on nanoparticles leading to their 
destabilization. Though, sucrose creates a glassy matrix and PLGA NPs are imobilizated within 
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it, preventing their aggregation and protect them against the mechanical stress of ice crystal. 
For this reason it was concluded that freeze-drying with cryo-protectant agents allows NP 
stability improvement during storage [94].  
UV-VIS measurements demonstrated that vitamin remained stable after this process. 
 
4.3 Calcitriol release from the PLGA nanoparticles 
 
The release profile of calcitriol entrapped in PLGA NPs was carried out in PBS (0.01 M, 
pH 7.4 at 37 °C). The attained calcitriol release curve is presented in figure 11.  
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Figure 11| In vitro release profile of calcitriol from PLGA NPs in PBS (0.01 M, pH 7.4) at 37 °C. 
 
In vitro drug release testing is an important tool in the quality control of drug delivery 
systems and it can be used as well for the prediction of in vivo drug kinetics. Since drug 
entrapped in the NPs is not bioavailable, the drug release from nanoparticles is a major 
determinant in its biological effect. Therefore, assessment of this parameter is very important 
in these types of systems. The in vitro release of drugs from nanocarriers may approximate the 
physiological drug release profile, mimicking the physiological pH and salt concentrations. 
PLGA NPs tend to exhibit a biphasic release pattern, characterized by an initial burst release, 
followed by a slower sustained release [6, 25]. As figure 11 shows, calcitriol released at 24 h 
was around 45%. This initial rapid release might be attributed to the release of the surface-
adsorbed vitamin. The calcitriol entrapped in NPs polymeric matrix was released in a later and 
more controlled manner, reaching a quasi-plateau between 96 and 168 hours. In fact, between 
fourth and seventh days, only approximately 5% of the encapsulated calcitriol was released. In 
aqueous medium, PLGA suffers biodegradation by hydrolytic cleavage of its esters linkages into 
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monomers [4-6, 23-27]. During hydrolysis, acidic degradation products accumulate inside the 
PLGA NPs and are responsible for reaction auto-catalysis [25, 26]. The hydrolytic breakdown 
also causes the formation of pores allowing the release of oligomers and monomers, resulting 
in bulk erosion [23]. Thus, the main pathways for the second phase calcitriol release in PLGA 
NPs are: drug diffusion through NP matrix, NP matrix hydrolysis and NP erosion [5, 6, 23, 26]. 
As NPs degradation is slow, the release between 48 and 168 hours may depend mainly of 
vitamin diffusion through the polymeric matrix and matrix erosion. Therefore features as drug 
physico-chemical properties and geometry of drug-loaded PLGA NPs (size and shape) exhibit a 
major impact on the release profile [6, 23, 26]. After 168 hours, the total calcitriol released 
reached around 80%. 
Several studies that developed PLGA NPs for the encapsulation of various drugs have 
reported this characteristic biphasic release profile from the nanocarriers in PBS at 37 °C [6, 
96-98]. These attained results allow concluding that the developed PLGA NPs are an adequate 
approach for the calcitriol transport and release, due to its biphasic and controlled pattern. 
 
4.4 Cell survival and growth inhibition by calcitriol-loaded NPs  
 
The in vitro cytotoxic effects on two pancreatic cancer cell lines, HPNE and S2-013, 
after treatment with calcitriol entrapped into the prepared PLGA NPs were assessed, 
comparatively to free calcitriol, in terms of cell survival and growth. Both cells incubated with 
0.1% ethanol and bare PLGA NPS during 72 hours had no significant effect on the cell survival 
(figure 12). The results prove that PLGA nanoparticles are biocompatible, showing no 
deleterious effects on the viability of the studied cell lines. 
 
Figure 12 | Cell survival after incubation period in S2-013 and HPNE cell lines. The figures shows data for cells 
treated with 20 mg.mL
-1
 of bare PLGA NPs and 0.1% ethanol as control. Percent cell survival is expressed relative to 
that of untreated control cells (null) that did not receive NPs or ethanol. Data represented as mean ± SD (n=3). 
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The effect of calcitriol at concentrations from 0.005 x 103 to 2.5 x 103 nM was tested 
with concentrations of PLGA in the range of 1 x 10-1 µg.mL-1 to 20 µg.mL-1. From figures 13 to 
16 and table 8, the attained results and all the determined values for IC50 and GI50, 
respectively, are presented. It was verified that both free and encapsulated calcitriol exhibit a 
concentration-related decrease in cell survival and growth in both cell lines (figures 13 and 14). 
The advantage of PLGA NPs was noticed for both HPNE and S2-013, with calcitriol-NPs being 
significantly (P≤0.05) more efficient than free calcitriol in inhibiting cell survival and growth 
(figures 13 and 14). Thus, drug delivery with this polymeric system improves calcitriol 
antineoplastic activity, resulting in significantly (P≤0.05) lower IC50 and GI50 values (table 8). For 
instance in 48 hours assay, free calcitriol inhibits the S2-013 cell growth in 50% when its 
concentration is of 0.78x103 nM (renewed daily, total of 2 administrations resulting in a 
cumulative concentration of 1.56x103 nM), which is about 3 fold higher than equivalent 
0.53x103 nM calcitriol of the loaded NPs (added only at t=0) which exhibit the same effect 
(table 8). The GI50 results for 48 and 72 hours demonstrate that the total dose of free calcitriol 
added to the cell lines was 3-3.5 times of the calcitriol NP dose to achieve 50% of cell growth.  
 
 
 
 
 
 
 
 
 
 
 
 
    
 
 
 
Figure 13| Cytotoxic effects of calcitriol free and entrapped in PLGA NPs after 48 hours treatment on two human 
pancreatic cell lines, S2-013 (A and B) cells and hTERT-HPNE (C and D), determined by SRB assay. (A) and (C) effects 
of calcitriol on cell survival; (B) and (D) effects of calcitriol on cell growth. Free calcitriol was supplemented daily due 
to its short half-life. Survival inhibition is presented as percent [(%)=T/C  x 100]; as growth inhibition [(%)=((T-T0)/(C-
T0))  x 100]. 
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Figure 14 | Cytotoxic effects of calcitriol free and entrapped in PLGA NPs after 72 hours treatment on two human 
pancreatic cell lines, S2-013 (A and B) cells and hTERT-HPNE (C and D), determined by SRB assay. (A) and (C) effects 
of calcitriol on cell survival; (B) and (D) effects of calcitriol on cell growth. Free calcitriol was supplemented daily due 
to its short half-life.  
 
Still, it is important to highlight that due to the calcitriol short half-life, the presented 
drug concentrations were added daily, unlike calcitriol loaded in NPs that was only added 
once, at time t0. So, in the 48 hours assay, 2.4 x 103 nM calcitriol loaded in PLGA NPs reduced 
the cell growth of S2-013 cell line to about 15 % compared with 30 % when calcitriol was 
administered alone at t=0 and t=24 hr (figure 13B). However, due to daily renewal, free 
calcitriol 2.4 x 103 nM corresponds to a cumulative concentration of 4.8 x 103 nM at 48 hours 
(two administrations of 2.4 x 103 nM) and 7.2 x 103 nM at 72 hours (three administrations of 
2.4 x 103 nM).  
Despite the NPs themselves already show an advantage compared to calcitriol alone 
renovated daily; if the comparison was made between loaded NPs and single-add free calcitriol 
instead of renewed daily calcitriol, that advantage would be much more evident as 
demonstrated by figure 16. As figure 15 depicts, for the same range of concentrations, 
calcitriol single-added at t=0 shows a decreased in vitro anti-tumor activity when comparing 
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with calcitriol daily renewed, resulting in IC50 (P≤0.05) value of 2.19 x 10
3 nM, compared to 2 
administrations of calcitriol (1.51 x 103 nM) in 48 hours (calcitriol total= 3.02 x 103 nM) to 
achieve the same effect. Thus, to use low calcitriol concentrations for comparing the efficacy 
of the calcitriol loaded NPs, free calcitriol daily renovation was performed in all assays. 
Due to calcitriol short half-life, daily renewal was necessary to maintain the 
concentration of vitamin D, increasing the frequency of administration and consequently use 
more drug than in the case of vitamin encapsulated in the PLGA nanoparticles. As a result, the 
obtained data prove that PLGA NPs enhance calcitriol antineoplasic activity, allowing reducing 
the administration frequency, as well to use low doses of drug.  
 
Table 8 | Cytotoxic effects of calcitriol on the survival and growth of both cell lines, S2-013 and HPNE, respectively. 
Results are expressed as IC50 and GI50 at 48 and 72 hours of exposure with calcitriol free and entrapped in PLGA NPs 
by SRB assay. Free calcitriol was supplemented daily to its short half-life.  
 
IC50 (103nM) GI50 (103nM) 
48 hours assay S2-013 hTERT-HPNE S2-013 hTERT-HPNE 
Calcitriol (renewed daily) 1.51 ± 0.05 1.95 ± 0.03 0.78 ± 0.01 1.25 ± 0.01 
Calcitriol loaded-PLGA NPs 1.10 ± 0.06 1.46 ± 0.05 0.53 ± 0.02 1.12 ± 0.04 
 
 72 hours assay 
Calcitriol (renewed daily) 0.61 ± 0.01 1.63 ± 0.01 0.48 ± 0.01 1.08 ± 0.01 
Calcitriol loaded-PLGA NPs 0.52 ± 0.01 1.22 ± 0.01 0.43 ± 0.01 0.83 ± 0.02 
 
The benefits of NPs could be explained by the efficient cell internalization of PLGA NPs 
as due to their rapid endo-lysosomal escape already reported by Panyam and co-workers [99]. 
It is expected an improvement of the intracellular delivery of encapsulated vitamin compared 
to the free one. This can be attributed to the fact that NPs may have been more readily 
internalized by an endocytosis mechanism [100], while free calcitriol may have been 
transported into cells by a passive diffusion mechanism, suggesting that the multi-drug 
resistance problem, effluxing of calcitriol out of cells by p-glycoprotein pump existing within 
cell membrane, might be circumvented by the nanoparticle approach [30, 100]. The efficient 
uptake of PLGA-NPs by S2-013 and hTERT-HPNE cells has been previously reported before by 
our group [85]. Also, despite calcitriol having a short half-life, its entrapment in PLGA NPs 
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allows vitamin protection, sustained and controlled delivery, avoiding drug degradation and 
inactivation.  
For both cell types, treatment with encapsulated and non-encapsulated calcitriol for 
72 hours had shown significantly (P≤0.05) more deleterious effects than 48 hours treatment. 
The sustained and controlled release of these PLGA NPs explain the attained results of 
calcitriol loaded NPs in terms of cell survival and cell growth after 48 and 72 hours (figures 13 
and 14). From these results, our conclusion is that a longstanding treatment presents more 
pronounced deleterious effect since these NPs are able to maintain drug concentrations. Also, 
it is quite relevant to analyze and compare the effect of free calcitriol and loaded NPs on 
hTERT -HPNE and S2-013 cell lines. The results shown in figures 13 and 14 demonstrated that 
the calcitriol deleterious effect is significantly (P≤0.05) higher in the cancer cell line, S2-013.  
IC50 and GI50 values for S2-013 cells are almost two fold higher than for hTERT –HPNE cells 
(table 8). Although the NPs potentiate the drug’s effect on the HPNE cell line likewise as for the 
pancreatic tumor cells, HPNE cells show more resistance to vitamin’s toxicity, whether 
calcitriol is encapsulated or not. For instance, while 50 nM calcitriol loaded in PLGA NPs reduce 
the cell growth of S2-013 cell line to about 80% after 48 hours, at the same concentration 
calcitriol-PLGA NPs do not show toxicity in the HPNE cell line (figure 13B and 13D).  
  
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 16 | Effects on cell survival of calcitriol free (single-
add) and  entrapped in PLGA NPs, after 48 hours treatment 
on S2-013 cell line, determined by SRB assay. Survival 
inhibition is presented as percent [(%)=T/C  x 100]. 
Figure 15 | Effects on cell survival of calcitriol free, single-
add and renewed daily, after 48 hours treatment on S2-013 
cell line, determined by SRB assay. Survival inhibition is 
presented as percent [(%)=T/C  x 100]. 
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5. CONCLUDING REMARKS AND FUTURE PERSPECTIVES  
 
Cancer is the main cause of death worldwide and its conventional therapy has several 
limitations since anticancer drugs act indiscriminately on both tumor and healthy tissues. 
Nanoparticles are promising candidates for anticancer drugs delivery, as they present 
numerous advantages over conventional chemotherapy such as improving the drug water 
solubility, protecting it from the macrophage uptake, thus enhancing the blood circulation 
time, and finally providing an increased and controlled release into the specific final target. 
Calcitriol, the active metabolite of Vitamin D3, is a potential anticancer agent. Although 
as other chemotherapeutic drugs, the use of Vitamin D3 also exhibits several drawbacks. These 
limitations are recently leading to numerous investigations in order to design and develop an 
ideal formulation for Vitamin D3 delivery to cancer cells. Although significant progress has been 
made, an ideal carrier has not yet been achieved. 
PLGA is one of the most promising biomaterials due to being biocompatible, 
biodegradable and FDA-approved, and having adjustable biodegradation rate and tunable 
mechanical properties. Its special features allow protection of drug from degradation and 
sustained release delivery. For these reasons, in this work, PLGA NPs were proposed to 
calictriol delivery to cancer cells.   
Calcitriol-loaded PLGA NPs were prepared by a single emulsion solvent evaporation 
method and stabilized with Pluronic F127. Formulation parameters were studied and discussed 
using cholecalciferol as a drug model to select the NP that presents adequate physicochemical 
characteristics for the calcitriol encapsulation and delivery into pancreatic cells. The studied 
formulation parameters were the vitamin/polymer ratio and sonication time. The prepared 
PLGA NPs exhibit a spherical shape, mean diameter ranging between 170 and 190 nm, low PdI 
values and negative zeta potential values. While cholecalciferol entrapment reached values of 
efficiency of approximately 83%, for calcitriol loaded-PLGA NPs the attained encapsulation 
efficiency values were lower (57%). The prepared NPs exhibited loading capacity values in the 
order of 5-8% and a process yield of about 57%. The prepared system is stable at storage 
conditions for several weeks and was lyophilized to increase its shelf-life. 1% sucrose was a 
cryoprotective agent suitable to preserve particle integrity after reconstitution of lyophilised 
drug-loaded PLGA nanoparticles. 
The prepared PLGA nanoparticles exhibited a biphasic release profile, as reported 
before in several published studies that developed PLGA NPs for the encapsulation of several 
drugs. Approximately 45% of calcitriol was released in the first 24 hours, which may be 
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correspondent to the surface-adsorbed vitamin. This burst release was followed by a slower 
sustained release phase, attributed to the calcitriol entrapped in the NPs polymeric matrix, 
reaching approximately 80% of released calcitriol after 7 days. 
The in vitro cytotoxic studies proved that bare PLGA NPs are biocompatible and also 
revealed that this nanosystem allowed maintaining and enhancing the antineoplastic effect of 
calcitriol against human pancreatic cancer cells. Moreover this system provides drug 
protection and prevention from degradation, increasing calcitriol half-life. Besides the 
enhanced drug bioavailability, this formulation may have better selectivity for target cancer 
cells and tissues, since, in a certain concentration range, calcitriol-NPs exhibit deleterious 
effects on the cancer cells, but not in the healthy cells.  
All these results suggest that the obtained nanoparticles could be good candidates for 
vitamin D3 release to animals and humans. Thus, we can also conclude that nanoencapsulation 
in PLGA NPs may offer a new and potentially effective administration strategy of calcitriol that 
overcomes the actual limitations as its bioavailability and toxicity.  
 
5.1 Future perspectives 
 
Several assays and experiments could have been conducted to upgrade the developed 
system as to improve its characterization, but were not possible to perform due to time 
restrictions and experimental problems. Although, the prepared PLGA nanoparticles have 
proved to be a promising new approach to calcitriol delivery to cancer cells, further 
development is required. For instance surface modification, with specific biomolecules or 
antibodies, may improve their targeting and accumulation in target-tissue as increase their 
bioavailability. 
Finally, in vivo tests using animal models, as pharmacokinetics and biodistribution 
studies would be interesting to evaluate in detail the system efficacy. However these studies 
would entail a costly investment.  
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APPENDIX 
 
A – Cholecalciferol calibration curve 
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Figure 17 | Cholcalciferoll calibration curve in 3.5% of ethyl acetate in an aqueous solution of 0.1% pluronic. Data 
vertical lines represent Standard Deviation (n=3). 
 
                                     
 
 
 
B – Calcitriol calibration curves 
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Figure 18| Calcitriol calibration curve in 3.5% of ethyl acetate in an aqueous solution of 0.1% pluronic. Data vertical 
lines represent Standard Deviation (n=3). 
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Figure 19| Calcitriol calibration curve in ethanol. Data vertical lines represent Standard Deviation (n=3). 
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